Selecta Biosciences - רווח נקי למניה ב-12 החודשים האחרונים RNAC

The EPS (TTM) market trend for Cartesian Therapeutics (RNAC) demonstrates a value of 90.30. Cartesian Therapeutics develops advanced mRNA CAR-T therapies that eliminate genomic risks and are available on an outpatient basis. However, the lack of recurring revenue and high production costs create financial threats. An innovative approach to cell modification for combating cancer and autoimmune profiles protects the business from competitors' pricing pressure.

Profit dynamics are critical for assessing the financial stability of Cartesian Therapeutics (RNAC). This metric measures the percentage change in earnings per share over a rolling year, neutralizing quarterly volatility. An analysis of the 12-month YoY change in net income per share reveals the actual efficiency of capital. In the context of labor-intensive cell therapy, this trend reflects the company's ability to scale its business despite a high dependence on the manual labor of scientists.